Sleevegate!
GM spies on its customers. Every minute of every day.
1. A novel therapy designed to clear toxic clumps of a protein thought to be responsible for Parkinson's disease has shown promise in early clinical trials. Produced by the US biotechnology company Vaxxinity, the immunotherapy candidate codenamed UB-312 is the first treatment shown to be capable of reducing concentrations of alpha-synuclein (α-syn) in cerebrospinal fluid, marking a significant step forward in slowing – or even halting – the disorder's progress. Though the results of the trial are yet to be published and peer reviewed, reports from company officials are optimistic, suggesting they're onto something big. (Sources: sciencealert.com, vaxxinity.com)
